Literature DB >> 11502511

Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model.

I Gustafsson1, E Löwdin, I Odenholt, O Cars.   

Abstract

An in vitro kinetic model was used to study the relation between pharmacokinetic and pharmacodynamic (PK-PD) parameters for antimicrobial effect, e.g., the time above MIC (T>MIC), maximum concentration in serum (C(max)), and area under the concentration-time curve (AUC). Streptococcus pyogenes and Escherichia coli were exposed to cefotaxime, and the activity of amoxicillin against four strains of Streptococcus pneumoniae with different susceptibilities to penicillin was studied. The drug elimination rate varied so that the T>MIC ranged from 20 to 100% during 24 h, while the AUC and/or the initial concentration (C(max)) were kept constant. For S. pyogenes and E. coli, the maximal antimicrobial effect (E(max)) at 24 h occurred when the antimicrobial concentration exceeded the MIC for 50 and 80% of the strains tested, respectively. The penicillin-susceptible pneumococci (MIC, 0.03 mg/liter) and the penicillin-intermediate strain (MIC, 0.25 mg/liter) showed maximal killing by amoxicillin at a T>MIC of 50%. For a strain for which the MIC was 2 mg/liter, C(max) needed to be increased to achieve the E(max). Under the condition that C(max) was 10 times the MIC, E(max) was obtained at a T>MIC of 60%, indicating that C(max), in addition to T>MIC, may be an important parameter for antimicrobial effect on moderately penicillin-resistant pneumococci. For the strain for which the MIC was 4 mg/liter, the reduction of bacteria varied from -0.4 to -3.6 log(10) CFU/ml at a T>MIC of 100%, despite an initial antimicrobial concentration of 10 times the MIC. Our studies have shown that the in vitro kinetic model is a useful complement to animal models for studying the PK-PD relationship for antimicrobial effect of antibiotics.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502511      PMCID: PMC90674          DOI: 10.1128/AAC.45.9.2436-2440.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms.

Authors:  P Moreillon; Z Markiewicz; S Nachman; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

2.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

3.  Effect of increased dosages of amoxicillin in treatment of experimental middle ear otitis due to penicillin-resistant Streptococcus pneumoniae.

Authors:  B Barry; M Muffat-Joly; P Gehanno; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

Review 4.  The post-antibiotic sub-MIC effect in vitro and in vivo.

Authors:  O Cars; I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

5.  Penetration of ampicillin and dicloxacillin into tissue cage fluid in rabbits: relation to serum and tissue protein binding.

Authors:  O Cars; C Henning; S E Holm
Journal:  Scand J Infect Dis       Date:  1981

6.  Penicillin pharmacodynamics in four experimental pneumococcal infection models.

Authors:  H Erlendsdottir; J D Knudsen; I Odenholt; O Cars; F Espersen; N Frimodt-Møller; K Fuursted; K G Kristinsson; S Gudmundsson
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

7.  Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media.

Authors:  R Dagan; C E Johnson; S McLinn; N Abughali; J Feris; E Leibovitz; D J Burch; M R Jacobs
Journal:  Pediatr Infect Dis J       Date:  2000-02       Impact factor: 2.129

8.  Clinical outcome of acute otitis media caused by pneumococci with decreased susceptibility to penicillin.

Authors:  B Barry; P Gehanno; M Blumen; I Boucot
Journal:  Scand J Infect Dis       Date:  1994

Review 9.  The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Authors:  J M Hyatt; P S McKinnon; G S Zimmer; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

10.  Penetration of cefotaxime and desacetylcefotaxime into brain abscesses in humans.

Authors:  J Sjölin; N Eriksson; P Arneborn; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

View more
  19 in total

1.  Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models.

Authors:  Jenny Dahl Knudsen; Inga Odenholt; Helga Erlendsdottir; Magnus Gottfredsson; Otto Cars; Niels Frimodt-Møller; Frank Espersen; Karl G Kristinsson; Sigurdur Gudmundsson
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

2.  Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.

Authors:  Roland R Regoes; Camilla Wiuff; Renata M Zappala; Kim N Garner; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 3.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

Review 4.  Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.

Authors:  Sofie Dhaese; Aaron Heffernan; David Liu; Mohd Hafiz Abdul-Aziz; Veronique Stove; Vincent H Tam; Jeffrey Lipman; Jason A Roberts; Jan J De Waele
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447

5.  Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli.

Authors:  Sara K Olofsson; Patricia Geli; Dan I Andersson; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

6.  Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.

Authors:  Elisabet I Nielsen; Anders Viberg; Elisabeth Löwdin; Otto Cars; Mats O Karlsson; Marie Sandström
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

7.  Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.

Authors:  Inga Odenholt; Elisabeth Löwdin; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

8.  Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

9.  Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

10.  Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infection.

Authors:  Jing Wang; Qi Shan; Huanzhong Ding; Chaoping Liang; Zhenling Zeng
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.